Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497060 | 1.00 | CTSK (0.57) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL7000046 | 1.00 | CTSK (0.57) | CTSKCTSBCTSSCTSLABCB1 | |
| Leucine SCHEMBL14693625 | 0.92 | CTSK (0.52) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL16272898 | 0.91 | CTSK (0.57) | CTSKCTSBCTSSCTSLABCB1 | |
| Leucine SCHEMBL4294227 | 0.90 | CTSK (0.50) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL26312471 | 0.90 | CTSK (0.56) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL2302062 | 0.89 | CTSK (0.49) | CTSKCTSBCTSSCTSLABCB1 | |
| Leucine SCHEMBL2302063 | 0.89 | CTSK (0.49) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL11306130 | 0.89 | CTSK (0.58) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL11306127 | 0.89 | CTSK (0.58) | CTSKCTSBCTSSCTSLABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE30496-E | Tripeptide derivatives with central nervous system activity and preparation thereof | AYERST, MCKENNA & HARRISON, LTD. (CA) | 1981-01-27 | — | — | US | claimed |
| US-4018912-A | Tripeptide derivatives with central nervous system activity and preparation thereof | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-04-19 | — | — | US | claimed |
| EP-4733307-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025070753-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | 中外製薬株式会社 | 2025-04-03 | — | — | WO | disclosed |
| CN-118354782-A | Compositions comprising peptide compounds for use in combination with surfactants | 中外制药株式会社 | 2024-07-16 | — | — | CN | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| CN-118176012-A | Compositions comprising a peptide compound and a surfactant | 中外制药株式会社 | 2024-06-11 | — | — | CN | disclosed |
| EP-4376834-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118043045-A | Novel spiropyrrolidine derived antiviral drugs | 英安塔制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0657173-A1 | Endoparasiticide drugs on a basis of open chain hexadepsipeptides | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0644883-A1 | ENNIATINES AND ENNIATINE DERIVATES USED TO CONTROL ENDOPARASITES | BAYER AG (DE) | 1995-03-29 | — | — | EP | disclosed |
| WO-1993025543-A2 | ENNIATINES AND ENNIATINE DERIVATES USED TO CONTROL ENDOPARASITES | BAYER AKTIENGESELLSCHAFT (DE) | 1993-12-23 | — | — | WO | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
| US-4250085-A | PHOSPHONATE-CONTAINING OLIGOPEPTIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-02-10 | — | — | US | disclosed |
| US-RE30496-E | Tripeptide derivatives with central nervous system activity and preparation thereof | AYERST, MCKENNA & HARRISON, LTD. (CA) | 1981-01-27 | — | — | US | disclosed |
| EP-0002822-A1 | Phosphorus containing peptide derivatives, their production, intermediates for their production and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-07-11 | — | — | EP | disclosed |
| US-4018912-A | Tripeptide derivatives with central nervous system activity and preparation thereof | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CTSK 1688/4885CTSB 829/4885CTSS 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.